Cryopreservation is a decisive step in CAR-T and other cell therapy workflows. Between manufacturing, release testing, shipping, and clinical administration, engineered cells are frozen and thawed at least once, and every freeze-thaw cycle is an opportunity to lose viability, cell number, and, critically, the engineered function that makes the product therapeutic. For CAR-T cells, that means preserving not only how many cells survive, but how many still express a functional chimeric antigen receptor (CAR).
Traditional freezing media that rely on serum and undefined components introduce variability and regulatory risk that are increasingly incompatible with clinical-grade manufacturing. This has driven demand for chemically defined, serum- and protein-free cell freezing media purpose-built for cell and gene therapy (CGT). The key question is whether such a medium can protect CAR-T viability, recovery, and CAR expression as well as, or better than, conventional solutions, including at the high cell densities used in manufacturing.
This article explains what chemically defined CGT cell freezing media are, why cryopreservation quality matters for CAR-T, and the factors that determine post-thaw performance, supported by data from CD19 CAR-T cells cryopreserved in Kryogene Cell Freezing Media - CGT.
What Is a Chemically Defined CGT Cell Freezing Media?
A chemically defined CGT cell freezing medium is a cryopreservation solution formulated from fully specified, serum- and protein-free components and engineered for cell and gene therapy manufacturing. Rather than depending on animal-derived serum for cryoprotection, it uses an optimized, defined formulation that minimizes ice crystal formation and preserves cell integrity through freezing, storage, and post-thaw recovery.
Compared with serum-containing solutions, a chemically defined CGT medium is designed to deliver high, reproducible post-thaw viability and functional recovery while removing undefined components, lot-to-lot variability, and adventitious-agent risk. Kryogene Cell Freezing Media - CGT is engineered specifically for CAR-T, NK, MSC, iPSC, and other advanced cell therapies, is manufactured under current Good Manufacturing Practice (cGMP) standards with USP-compliant raw materials, and is provided ready-to-use to eliminate preparation steps.
Why Cryopreservation Quality Matters for CAR-T Cells
CAR-T products are living drugs, and their potency depends on the survival and function of the engineered cells at the moment of infusion. Poor cryopreservation can reduce post-thaw viability, lower the number of viable cells recovered relative to the dose formulated, and stress cells in ways that impair proliferation and effector function. Because dosing is defined by viable CAR-positive cells, losses at the freezing step translate directly into weaker or out-of-specification product.
Cryopreservation also occurs at multiple points across a cell therapy process, from drug substance to final drug product, so the freezing medium influences quality at more than one stage. A medium that consistently preserves viability, recovery, and CAR expression, and that does so at the concentrated densities used in manufacturing, protects both product quality and process reproducibility. This is why the freezing medium should be treated as a critical raw material, not a commodity.
How Chemically Defined CGT Freezing Media Protect CAR-T Cells
1. Chemically Defined, Serum- and Protein-Free Formulation
The foundation of reproducible cryopreservation is a defined formulation. By removing serum and protein, a chemically defined CGT medium eliminates undefined composition, lot-to-lot variability, and the risk of adventitious agents, while remaining compatible with xeno-free, clinical-grade workflows. Optimized cryoprotection minimizes ice crystal formation to preserve membrane and receptor integrity during freeze-thaw cycles, which is the physical basis for retaining both viability and CAR expression.
2. High Post-Thaw Viability and Viable Cell Recovery
Viability is the first benchmark after thawing, but total viable cell recovery is what determines dose. A high-quality CGT medium should maintain high viability immediately after thaw and after recovery culture, together with strong viable cell recovery. In testing with three independent CD19 CAR-T batches frozen at 5 x 10^6 cells/mL, CAR-T cells cryopreserved in Kryogene Cell Freezing Media - CGT maintained high post-thaw viability at 0h and 24h, with performance comparable to a leading competitor.
Figure 1. Post-thaw performance of three CD19 CAR-T batches cryopreserved at 5 x 10^6 cells/mL in Kryogene Cell Freezing Media - CGT versus a competitor. Cell viability (%), CAR expression (%), and cell density (cells/mL) were assessed before freezing and at 0h and 24h post-thaw. CAR-T cells retained high viability and recovered CAR expression by 24h, with cell density returning to expected ranges after recovery.
As Figure 1 shows, viability and cell density recover to expected ranges after thawing, confirming that the defined formulation supports both cell survival and usable yield, the two attributes that most directly control CAR-T dose.
3. Preserved CAR Expression and Cell Identity
For CAR-T, viability alone is insufficient; the engineered receptor must survive the process. A transient dip in detectable CAR expression immediately after thaw is common as cells recover, and the meaningful question is whether expression returns. In the same study, CAR expression recovered by 24h post-thaw in cells frozen with the chemically defined CGT medium (Figure 1, CAR Expression panel), indicating that receptor display and cell identity are preserved through cryopreservation. Because CAR expression drives target engagement and potency, this recovery is essential to maintaining a therapeutically active product.
4. Reliable Performance at High Cell Densities
Manufacturing often requires freezing cells at high concentration to reduce volume, simplify logistics, and support flexible dosing. High-density cryopreservation is more demanding, because concentrated cells compete for cryoprotectant and generate more metabolic and osmotic stress. A robust CGT medium must therefore perform not only at standard densities but also at the concentrated densities used in production.
Figure 2. The same post-thaw assessment performed at a high freezing density of 2.5 x 10^7 cells/mL. Kryogene Cell Freezing Media - CGT maintained high post-thaw cell viability and recovery of CAR expression by 24h even at this concentrated density, supporting high-density cell banking for CAR-T manufacturing.
As Figure 2 shows, viability and CAR expression are preserved even at 2.5 x 10^7 cells/mL, a five-fold higher concentration than the standard test. This tolerance to high-density freezing is a practical advantage for CGT manufacturing, where concentrated, well-preserved lots streamline storage, shipping, and dose preparation.
5. cGMP, Clinical-Grade Manufacturing, and Regulatory Alignment
For clinical products, formulation is only half the story; how the medium is made determines whether it can be used in a regulated process. A CGT freezing medium should be manufactured under cGMP standards with USP-compliant raw materials and supported by lot-specific quality documentation, so it aligns with global regulatory expectations for advanced therapies. This alignment reduces qualification burden and de-risks the path from research to clinic.
6. Batch-to-Batch Consistency via Closed, Single-Use Manufacturing
Consistency depends on the quality system behind the product. A closed, disposable (single-use) manufacturing process prevents cross-contamination between batches, while rigorous quality control guarantees uniform performance across production lots. For CAR-T programs that run over months or years and consume multiple lots of freezing medium, this batch-to-batch consistency is what allows post-thaw results to be compared and trusted over the life of the program.
Quick reference: what to evaluate when selecting a CGT cryopreservation medium
| Evaluation Area | Key Question |
| Formulation | Is it chemically defined, serum- and protein-free? |
| Viability & recovery | Are high post-thaw viability and viable cell recovery shown? |
| Functional preservation | Is CAR expression / cell identity recovered after thaw? |
| High-density performance | Is performance validated at concentrated freezing densities? |
| Manufacturing & QC | Is it cGMP/USP-aligned with closed single-use production? |
Beyond CAR-T: NK, MSC, and iPSC Applications
Although CAR-T is a demanding test case, a chemically defined CGT medium is engineered to support the broader cell therapy landscape, including NK cells, mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs). In parallel testing with umbilical cord-derived MSCs, cells cryopreserved in Kryogene Cell Freezing Media - CGT retained characteristic surface markers (CD90, CD73, CD105 positive; CD45, CD34 negative), maintained high post-thaw viability and normal doubling times across passages, and preserved tri-lineage differentiation into bone, cartilage, and fat. This confirms that the medium preserves not just survival but the identity and function that define each therapeutic cell type.
Practical Considerations for CAR-T Cryopreservation
Selecting a well-designed medium is necessary but not sufficient; the whole process must be controlled. To realize consistent post-thaw outcomes, standardize cell health before freezing, cell density at freezing, container format, cooling rate (controlled-rate freezing for sensitive cells), hold time before freezing, liquid nitrogen storage conditions, thawing speed, and post-thaw dilution or recovery before assays. Assess viability, viable cell recovery, and CAR expression at multiple time points, including after recovery culture, rather than at a single immediate-post-thaw reading, and reserve enough medium from a single lot to cover a study or manufacturing campaign.
Kryogene Cell Freezing Media - CGT
Kryogene Cell Freezing Media - CGT is a chemically defined, serum- and protein-free cryopreservation solution developed for next-generation cell therapies. It supports high cell viability and functional integrity throughout freezing, storage, and post-thaw recovery, and is engineered for CAR-T, NK, MSC, iPSC, and other advanced cell therapies.
Key features and benefits:
• Optimized for cell therapies: engineered for CAR-T, NK, MSCs, iPSCs, and other advanced modalities
• Superior cryoprotection: minimizes ice crystal formation to preserve cell integrity through freeze-thaw
• High viability retention: consistent cell function and recovery post-thaw, including at high freezing densities
• Clinical-grade manufacturing: cGMP standards with USP-compliant raw materials and regulatory alignment
• Ready-to-use formulation: eliminates preparation steps, enhancing reproducibility and workflow efficiency
• Batch-to-batch consistency: closed, single-use manufacturing prevents cross-contamination
The product is supplied as 100 mL in a bottle (Cat. No. AR0008-100) or bag (Cat. No. AR0008-100B) and stored at 2-8 degrees C. Kryogene is the cryobiology brand of MileCell, a recognized pioneer in primary cell research based in San Diego, California, with products manufactured under ISO 9001, ISO 14001, and ISO 45001 systems. The Kryogene range also includes Cell Freezing Media - Serum Free for complementary cryopreservation needs.
FAQ: Chemically Defined CGT Cell Freezing Media
Can a chemically defined CGT medium preserve CAR-T cells as well as conventional media?
Yes. In testing with three CD19 CAR-T batches, Kryogene Cell Freezing Media - CGT maintained high post-thaw viability, viable cell recovery, and recovered CAR expression by 24h, with performance comparable to a leading competitor, while offering the reproducibility and regulatory advantages of a serum- and protein-free, cGMP-manufactured formulation.
Does CAR expression survive freezing and thawing?
A transient decrease in detectable CAR expression can occur immediately after thaw as cells recover. In the data shown, CAR expression recovered by 24h post-thaw, indicating that receptor display and cell identity are preserved through cryopreservation when a suitable medium is used.
Can CAR-T cells be frozen at high cell densities?
Yes. Kryogene Cell Freezing Media - CGT maintained high post-thaw viability and CAR expression recovery at 2.5 x 10^7 cells/mL, a five-fold higher density than the standard 5 x 10^6 cells/mL test, supporting concentrated cell banking for manufacturing and flexible dose preparation.
Why choose a serum- and protein-free CGT freezing medium for cell therapy?
A chemically defined, serum- and protein-free medium removes undefined components, lot-to-lot variability, and adventitious-agent risk, and, when manufactured under cGMP with USP-compliant raw materials and closed single-use processing, aligns with regulatory expectations for clinical-grade cell and gene therapy.
Conclusion
For CAR-T and other cell therapies, the freezing medium is a critical determinant of product quality. A chemically defined CGT cell freezing medium protects the attributes that define a potent CAR-T product, high post-thaw viability, strong viable cell recovery, and recovered CAR expression, while preserving performance at the concentrated densities used in manufacturing. Combined with cGMP, clinical-grade production and closed, single-use manufacturing for batch-to-batch consistency, it gives cell therapy teams reproducible, defensible cryopreservation from research through clinical supply.
Data from CD19 CAR-T cells frozen at both standard and high densities show that a serum- and protein-free formulation can preserve viability, recovery, and CAR expression, making chemically defined CGT freezing media a credible foundation for advanced therapy workflows.
Looking for a chemically defined, cGMP cryopreservation solution for your CAR-T or cell therapy program? Explore Kryogene Cell Freezing Media - CGT, or contact the MileCell team to request product information, lot-specific data, or a quote.
Contact: Info@milecell-bio.com | Website: www.milecell-bio.com
